<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00632840</url>
  </required_header>
  <id_info>
    <org_study_id>UWA_DC012008</org_study_id>
    <nct_id>NCT00632840</nct_id>
  </id_info>
  <brief_title>Pharmacological Regulation of Fat Transport in Metabolic Syndrome</brief_title>
  <official_title>Regulation of Lipoprotein Kinetics by Atorvastatin and Fenofibrate With the Metabolic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Western Australia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart Foundation, Australia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Western Australia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether atorvastatin and fenofibrate are effective
      in the treatment of lipid disorders in obese, insulin resistant subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Insulin resistance is a heterogeneous metabolic disorder of complex etiology. It underpins
      dyslipoproteinemia, a key feature of the metabolic syndrome (MetS) that independently
      predicts cardiovascular disease (CVD). Hypertriglyceridemia, the most consistent lipid
      disorder in subjects with obesity and type 2 diabetes mellitus, is chiefly a consequence of
      overproduction and delayed clearance of triglyceride-rich lipoproteins (TRLs). Although the
      precise mechanisms involved are incompletely understood, experimental and clinical evidence
      suggests that elevated apolipoprotein (apo) C-III may play a crucial role in the
      dysregulation of TRL metabolism. investigating the effects of these agents on VLDL-apoC-III
      kinetics. In this study, we aimed to examine the effect of two lipid-regulating agents,
      atorvastatin and fenofibrate on VLDL-apoC-III transport. We hypothesized that atorvastatin
      and fenofibrate would have similar effects on apoC-III transport by decreasing the production
      and increasing the catabolism of VLDL-apoC-III.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2001</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">December 2002</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>VLDL-apoC-III transport rate</measure>
    <time_frame>5 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Obesity</condition>
  <condition>Lipid Disorders</condition>
  <condition>Hypertriglyceridemia</condition>
  <condition>Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>P</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Feno</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fenofibrate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ATV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Atorvastatin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin and fenofibrate</intervention_name>
    <description>atorvastatin (40mg/day) fenofibrate (200mg/day)</description>
    <arm_group_label>P</arm_group_label>
    <arm_group_label>Feno</arm_group_label>
    <arm_group_label>ATV</arm_group_label>
    <other_name>Lipitor</other_name>
    <other_name>Lofibra</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        any three of the followings

          -  waist circumference &gt;102cm

          -  triglycerides &gt;1.7 mmol/L

          -  HDL-cholesterol &lt;1.05 mmol/L

          -  blood glucose &gt;6.1 mmol/L

          -  blood pressure &gt;130/85mmHg

        Exclusion Criteria:

          -  plasma cholesterol &gt;7mmo/L

          -  triglycerides &gt;4.5mmo/L

          -  diabetes mellitus (defined by oral glucose tolerance test)

          -  CVD

          -  consumption of &gt;30g alcohol/day

          -  use of agents affecting lipid metabolism

          -  APOE2/E2 genotype, macroproteinuria

          -  creatinaemia (&gt;120umol/L)

          -  hypothyroidism

          -  abnormal liver and muscle enzymes.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dick C Chan, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Western Australia</affiliation>
  </overall_official>
  <verification_date>February 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 20, 2008</study_first_submitted>
  <study_first_submitted_qc>February 29, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 11, 2008</study_first_posted>
  <last_update_submitted>February 29, 2008</last_update_submitted>
  <last_update_submitted_qc>February 29, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 11, 2008</last_update_posted>
  <responsible_party>
    <name_title>Gerald F Watts</name_title>
    <organization>University of Western Australia</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Metabolic Syndrome X</mesh_term>
    <mesh_term>Hypertriglyceridemia</mesh_term>
    <mesh_term>Lipid Metabolism Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Fenofibrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

